ArQule, Inc. (ARQL) Sets 52-Week High

May 16, 2018 - By Alma Kearns

ArQule, Inc. (NASDAQ:ARQL) Corporate Logo

Today 52 week high was reached by ArQule, Inc. (NASDAQ:ARQL) with $3.53 price target or 3.00 % above today’s $3.43 share price. On May, 16 it was published by Barchart.com. It has $298.40M market cap. At our $3.53 price target, the company worth will be $8.95 million more.

ARQL hit $3.425 during the last trading session after $0.175 change.Currently ArQule, Inc. is uptrending after 180.00% change in last May 16, 2017. ARQL has 531,058 shares volume. ARQL outperformed by 168.45% the S&P 500.

ArQule, Inc. (NASDAQ:ARQL)’s earnings release is awaited by WallStreet on August, 3, Faxor reports. Analysts predict $-0.05 earnings per share, which is $0.05 up or 50.00 % from 2017’s $-0.1 earnings per share. After $-0.07 earnings per share was announced last quarter, analysts now see EPS growth of -28.57 % for ArQule, Inc..

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

In total 5 analysts cover Arqule (NASDAQ:ARQL). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $5 highest and $3.0 lowest price target Arqule has $4.13 average price target or 20.58% above the current ($3.425) price. 5 are the (NASDAQ:ARQL)’s analyst reports since December 14, 2017 according to StockzIntelligence Inc. On Thursday, December 14 Needham upgraded ArQule, Inc. (NASDAQ:ARQL) to “Buy” rating. On Friday, February 2 the firm has “Buy” rating given by FBR Capital. In Monday, February 12 report B. Riley & Co maintained the stock with “Buy” rating. On Thursday, April 5 the stock of ArQule, Inc. (NASDAQ:ARQL) earned “Buy” rating by Leerink Swann.

There’s an important ArQule, Inc. (NASDAQ:ARQL) news published by Seekingalpha.com. It’s an item titled: “ArQule’s (ARQL) CEO Paolo Pucci on Q1 2018 Results – Earnings Call Transcript” on May 07, 2018.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.The firm is valued at $298.40 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.Currently it has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.